Remove tag predictive-biomarkers
article thumbnail

A broad range of unmet needs remains in the immuno-oncology space

Pharmaceutical Technology

IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000. There were also personalised care-related unmet needs identified, and this included the need for better predictive biomarkers. Cost-related unmet needs also scored highly.

article thumbnail

After a slow start for expensive CAR-T therapies, drug developers revisit oral therapies for blood cancer

pharmaphorum

price tag of $475,000 when it was first launched in 2017 – and it becomes apparent that these may not be desirable treatment options for every patient and in every setting. Among the patients treated at the RP2D, six out of seven had reduction or stabilisation of serum-free light chains – a biomarker that indicates the presence of myeloma.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

pharmaphorum

ICER argues that Aduhelm was effectively approved on the strength of a biomarker – removing amyloid from the brain – rather than clinical outcomes, which is “puzzling” as other drugs have been shown to remove amyloid from the brain yet failed to help patients. .” billion in 2027.

FDA 98
article thumbnail

Putting complex medicines under the microscope

European Pharmaceutical Review

For example, many small molecules can pass through the plasma membrane by diffusion to reach their target, whereas the tissue penetration, cellular uptake and intracellular trafficking of complex medicines can be difficult to predict. Physical characterisation.